Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Utah Medical Products/Vital Signs Inc.

This article was originally published in The Gray Sheet

Executive Summary

Utah Medical Products/Vital Signs Inc.: Firms enter agreement under which Vital Signs will market Utah Medical's Deltran IV disposable blood pressure transducer (DPT) in the U.S. Manufactured via an automated process, the Deltran IV is a lower cost version of Utah Medical's hand-assembled Deltran II DPT, which is marketed in the U.S. by Baxter under the name Uniflow. The agreement follows Utah Medical's March announcement that it would seek new marketing partners for the Deltran line due to Baxter's decision to cut back its distribution of the Deltran II and to phase out distribution of Utah Medical's Summit DPT ("The Gray Sheet" March 11, I&W-7). The company notes that it may be nearing another marketing agreement for Deltran IV with a "significant medical monitoring equipment company in the U.S."...

You may also be interested in...

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts